Clinical Trial Detail

NCT ID NCT01869114
Title Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Thomas Jefferson University
Indications

acute myeloid leukemia

bone marrow cancer

Therapies

Azacitidine + Sirolimus

Age Groups: adult

No variant requirements are available.